Skip to main content

Table 3 Association of placement of permanent vascular access with attribution of end-stage renal disease to systemic lupus erythematosus vs. other causes, among U.S. incident hemodialysis patients who started dialysis in 2010 with only a catheter in place: sensitivity analyses

From: Comparison of vascular access outcomes in patients with end-stage renal disease attributed to systemic lupus erythematosus vs. other causes: a retrospective cohort study

Model No. (%) with permanent access placed within 1 year Hazard ratio (95 % CI) for placement of permanent vascular access, SLE-attributed vs. other ESRD
Unadjusted Adjusted for demographics Adjusted for demographics + clinical
Primary analysis     
 SLE-attributed ESRD 177 (46.1 %) 0.74 (0.64-0.86) 0.94 (0.81-1.09) 1.00 (0.86-1.17)
 Other ESRD 22,076 (54.5 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.001 <0.001 0.42 >0.9
Excluding patients <18 years olda     
 SLE-attributed ESRD 171 (46.2 %) 0.74 (0.64-0.86) 0.92 (0.79-1.08) 0.98 (0.84-1.15)
 Other ESRD 22,053 (54.6 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.001 <0.001 0.31 0.82
Only among patients with Medicare at ESRD startb     
 SLE-attributed ESRD 67 (58.3 %) 0.77 (0.60-0.99) 0.83 (0.65-1.07) 0.83 (0.65-1.07)
 Other ESRD 15,635 (64.0 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.20 0.04 0.15 0.15
SLE and other GN compared to other ESRDc     
 SLE-attributed ESRD 177 (46.1 %) 0.73 (0.63-0.85) 0.93 (0.80-1.08) 0.97 (0.83-1.14)
 Other GN-attributed ESRD 1,219 (48.6 %) 0.83 (0.78-0.88) 0.91 (0.86-0.96) 0.94 (0.89-1.00)
 Other ESRD 20,857 (54.9 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P <0.001 <0.001/<0.001 0.35/<0.001 0.74/0.06
Matched analysisd     
SLE-attributed ESRD 177 (46.1 %) 0.85 (0.71-1.02) 0.88 (0.73-1.06) 0.93 (0.77-1.13)
Other ESRD 350 (51.7 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.08 0.09 0.17 0.48
Events prior to 90 days included on day 91     
 SLE-attributed ESRD 177 (46.1 %) 0.76 (0.65-0.88) 0.94 (0.81-1.10) 1.00 (0.86-1.17)
 Other ESRD 22,076 (54.5 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.001 <0.001 0.46 >0.9
Events prior to 90 days excludede     
 SLE-attributed ESRD 142 (40.7 %) 0.93 (0.79-1.10) 1.05 (0.89-1.25) 1.07 (0.91-1.27)
 Other ESRD 13,653 (42.6 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.48 0.41 0.56 0.42
  1. AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, GN glomerulonephritis, SLE systemic lupus eythematosus. Demographics: age (continuous), sex, race; clinical: body mass index (continuous), smoking, congestive heart failure, diabetes, and peripheral vascular disease
  2. aExcluding n = 162 patients (14 SLE, 148 other) who were <18 years old
  3. bExcluding n = 16,374 patients (269 SLE, 16,105 other) without Medicare at ESRD start
  4. cOther GN included 2,511 patients with CMS-2728 ICD-9 codes for attributed cause of glomerulonephritis (582.9, 582.1, 583.1, 583.21, 583.22, 583.81, 583.82, 583.4, 580.0, and 582.0) or secondary glomerulonephritis/vasculitis (excluding SLE-ESRD; 287.0, 710.1, 283.11, 446.0, 446.4, 583.92, 446.20, 446.21, and 583.91)
  5. dAmong n = 1061 patients, including 384 SLE patients and 677 matched non-SLE patients, using 2:1 matching on age group (<30, 30–49, and >50 years), sex (female and male), and race (black and not black). Models stratified on matching variables to account for matching
  6. eExcluding n = 8,491 patients (35 SLE, 8,456 other) with follow-up time <90 days